Connect with us

Business

Bristol-Myers gets ‘potentially revolutionary medicine’ in MyoKardia deal, CEO says – CNBC

“MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease,” Bristol-Myers Squibb CEO Gi…

post featured image
ADVERTISEMENT

Bristol-Myers Squibb CEO Giovanni Caforio told CNBC’s Jim Cramer on Monday why the pharmaceutical company paid a premium for heart drugs company MyoKardia.
Bristol Myers announced earlier that day it would dish out $13 billion for MyoKardia, whose stock surged double digits during the session to close short almost five points from Bristol Myers’ $225 offer price.
“MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease, …

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
22 Best Coffee Maker Deals for Black Friday and Cyber Monday (2021): Drip, Grinders, Espresso – WIRED
Article feature image
Deming Walmart store closed due to bomb threat – KOAT Albuquerque